We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NIXX:NASDAQNixxy, Inc. Analysis

Data as of 2026-06-18 - not real-time

$1.05

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Nixxy, Inc. (NIXX) is trading at $1.05, just below its calculated resistance of $1.13 and comfortably above the $0.49 support level, with the 20‑day SMA (0.77) and 50‑day SMA (0.70) both lying beneath the current price, indicating short‑term price momentum. The MACD histogram is positive (0.023) and the signal line is bullish, while the RSI sits at 68, suggesting the stock is approaching overbought territory but has not yet peaked. Volume is increasing and the 30‑day volatility is extreme at 145%, reflecting a highly speculative trading environment.
Fundamentally, NIXX reports a 22% revenue growth year‑over‑year but suffers from negative gross (0.07%), operating (‑4.2%) and profit margins (‑7.9%), a negative EBITDA of $‑4.9 M, and a distressed cash‑flow profile with operating cash flow of $‑3.1 M. The balance sheet shows a high debt‑to‑equity ratio of 10.5 and a price‑to‑book multiple of 3.42, while the price‑to‑sales ratio is modest at 0.24. No dividend is paid, and analysts have not issued coverage. The only material news point is a pending LOI with Tachyon9 for a large AI infrastructure build‑out, which could provide a catalyst if the transaction closes, but the strategic impact remains uncertain.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • RSI nearing overbought levels
  • Extreme short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Negative earnings and cash‑flow trends
  • High debt‑to‑equity ratio
  • Lack of dividend and analyst coverage

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Potential upside from AI infrastructure LOI
  • Revenue growth despite margin compression
  • Low price‑to‑sales ratio offering speculative entry

Key Metrics & Analysis

Financial Health

Revenue Growth2205.40%
Profit Margin-7.88%
ROE-113.21%
ROA-33.83%
Debt/Equity10.51
P/B Ratio3.4
Op. Cash Flow$-3113000
Free Cash Flow$-1259780
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI68.1
Support$0.49
Resistance$1.13
MA 20$0.77
MA 50$0.70
MA 200$1.02
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.23
Volatility145.21%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.